These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
68. Blocking interleukin-6 signaling inhibits cell viability/proliferation, glycolysis, and colony forming activity of human medulloblastoma cells. Chen X; Wei J; Li C; Pierson CR; Finlay JL; Lin J Int J Oncol; 2018 Feb; 52(2):571-578. PubMed ID: 29207075 [TBL] [Abstract][Full Text] [Related]
69. Oncogenic context shapes the fitness landscape of tumor suppression. Blair LM; Juan JM; Sebastian L; Tran VB; Nie W; Wall GD; Gerceker M; Lai IK; Apilado EA; Grenot G; Amar D; Foggetti G; Do Carmo M; Ugur Z; Deng D; Chenchik A; Paz Zafra M; Dow LE; Politi K; MacQuitty JJ; Petrov DA; Winslow MM; Rosen MJ; Winters IP Nat Commun; 2023 Oct; 14(1):6422. PubMed ID: 37828026 [TBL] [Abstract][Full Text] [Related]
70. Spatial aspects of oncogenic signalling determine the response to combination therapy in slice explants from Kras-driven lung tumours. Närhi K; Nagaraj AS; Parri E; Turkki R; van Duijn PW; Hemmes A; Lahtela J; Uotinen V; Mäyränpää MI; Salmenkivi K; Räsänen J; Linder N; Trapman J; Rannikko A; Kallioniemi O; Af Hällström TM; Lundin J; Sommergruber W; Anders S; Verschuren EW J Pathol; 2018 May; 245(1):101-113. PubMed ID: 29443392 [TBL] [Abstract][Full Text] [Related]
71. The deubiquitylase OTUD3 stabilizes GRP78 and promotes lung tumorigenesis. Du T; Li H; Fan Y; Yuan L; Guo X; Zhu Q; Yao Y; Li X; Liu C; Yu X; Liu Z; Cui CP; Han C; Zhang L Nat Commun; 2019 Jul; 10(1):2914. PubMed ID: 31266968 [TBL] [Abstract][Full Text] [Related]
72. ERO1L promotes IL6/sIL6R signaling and regulates MUC16 expression to promote CA125 secretion and the metastasis of lung cancer cells. Lei Y; Zang R; Lu Z; Zhang G; Huang J; Liu C; Wang Z; Mao S; Che Y; Wang X; Zheng S; Fang L; Sun N; He J Cell Death Dis; 2020 Oct; 11(10):853. PubMed ID: 33056994 [TBL] [Abstract][Full Text] [Related]
74. The integrated stress response in the induction of mutant KRAS lung carcinogenesis: Mechanistic insights and therapeutic implications. Koromilas AE Bioessays; 2022 Aug; 44(8):e2200026. PubMed ID: 35587163 [TBL] [Abstract][Full Text] [Related]
75. Reduced IL-6 levels and tumor-associated phospho-STAT3 are associated with reduced tumor development in a mouse model of lung cancer chemoprevention with myo-inositol. Unver N; Delgado O; Zeleke K; Cumpian A; Tang X; Caetano MS; Wang H; Katayama H; Yu H; Szabo E; Wistuba II; Moghaddam SJ; Hanash SM; Ostrin EJ Int J Cancer; 2018 Apr; 142(7):1405-1417. PubMed ID: 29134640 [TBL] [Abstract][Full Text] [Related]
76. A Functional Taxonomy of Tumor Suppression in Oncogenic KRAS-Driven Lung Cancer. Cai H; Chew SK; Li C; Tsai MK; Andrejka L; Murray CW; Hughes NW; Shuldiner EG; Ashkin EL; Tang R; Hung KL; Chen LC; Lee SYC; Yousefi M; Lin WY; Kunder CA; Cong L; McFarland CD; Petrov DA; Swanton C; Winslow MM Cancer Discov; 2021 Jul; 11(7):1754-1773. PubMed ID: 33608386 [TBL] [Abstract][Full Text] [Related]
77. RANK rewires energy homeostasis in lung cancer cells and drives primary lung cancer. Rao S; Sigl V; Wimmer RA; Novatchkova M; Jais A; Wagner G; Handschuh S; Uribesalgo I; Hagelkruys A; Kozieradzki I; Tortola L; Nitsch R; Cronin SJ; Orthofer M; Branstetter D; Canon J; Rossi J; D'Arcangelo M; Botling J; Micke P; Fleur L; Edlund K; Bergqvist M; Ekman S; Lendl T; Popper H; Takayanagi H; Kenner L; Hirsch FR; Dougall W; Penninger JM Genes Dev; 2017 Oct; 31(20):2099-2112. PubMed ID: 29118048 [TBL] [Abstract][Full Text] [Related]